白蛋白结合型紫杉醇联合顺铂二线治疗晚期胃癌的疗效

Clinical efficacy of second line chemotherapy with abraxane combined with cisplatinin for advanced gastric cancer

目的观察白蛋白结合型紫杉醇(abraxane)联合顺铂二线治疗晚期胃癌的疗效和安全性。方法复发、转移胃癌患者12例,均接受过一线化疗。二线化疗方案:abraxane 125mg/m^2,第1天和第8天;顺铂80~100mg/m^2,分为第2天~第4天。每3周重复1次,至少完成2个周期二线化疗。结果治疗后,12例患者中,部分缓解7例,病情稳定3例,病情进展2例。有效率58.33%,疾病控制率83.33%;疾病进展时间4.5个月。不良反应可以耐受;未发生过敏反应。结论对接受过一线化疗的晚期胃癌患者,采用abraxane联合顺铂二线化疗中仍有较好的疗效,不良反应可耐受。

Objective To investigate the efficacy and safety of second line chemotherapy with albumin-bound paclitaxel（abraxane）combined with cisplatin in advanced gastric cancer.Methods The second line chemotherapy with abraxane combined with cisplatin was performed in 12 patients with advanced gastric cancer,who received rescue chemotherapy after relapse and metastasis.The second line chemotherapy included abraxane 125 mg/m^2,D1 and D8,and cisplatin 80-100 mg/m^2 in D2-D4,which were repeated with an interval of three weeks.The chemotherapy was performed for at least 2complete cycles of treatment.Results Twelve patients after the second line chemotherapy,7 cases showed partial remission（PR）,3 cases stable disease（SD）,2cases progress disease（PD）.The responsive rate（RR）was 58.33%,disease control rate（DCR）was 83.33%,and time to progress（TTP）was 4.5 months.The adverse effects were mild and tolerable.Conclusion The second line chemotherapy with abraxane combined with cisplatin remains effective in the patients with advanced gastric cancer after the first line chemotherapy with tolerable adverse effects.